Single-centre, single-blinded, randomised, parallel group, feasibility study protocol investigating if mandibular advancement device treatment for obstructive sleep apnoea can reduce nocturnal gastro-oesophageal reflux (MAD-Reflux trial)

Saoirse O'Toole*, Rebecca Moazzez, Gabriella Wojewodka, Sebastian Zeki, Jafar Jafari, Katherine Hope, Andrew Brand, Zoe Hoare, Suzanne Scott, Kodchawan Doungsong, Victory Ezeofor, Rhiannon Tudor Edwards, Panagis Drakatos, Joerg Steier

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Downloads (Pure)

Abstract

Introduction Just under half of patients with obstructive sleep apnoea (OSA) also have gastro-oesophageal reflux disease (GORD). These conditions appear to be inter-related and continual positive airway pressure (CPAP) therapy, the gold standard treatment for OSA to prevent airway collapse, has been shown to reduce GORD. As the impact of mandibular advancement devices, a second-line therapy for OSA, on GORD has yet to be investigated, a feasibility study is needed prior to a definitive trial. Methods This will be a single-centre, single-blinded, tertiary-care based, interdisciplinary, parallel randomised controlled study. Potential OSA participants presenting to the sleep department will be pre-screened for GORD using validated questionnaires, consented and invited to receive simultaneous home sleep and oesophageal pH monitoring. Those with confirmed OSA and GORD (n=44) will be randomly allocated to receive either CPAP (n=22) or MAD therapy (n=22). Following successful titration and 3 weeks customisation period, participants will repeat the simultaneous sleep and oesophageal pH monitoring while wearing the device. The number of patients screened for recruitment, drop-out rates, patient feedback of the study protocol, costs of interventions and clinical information to inform a definitive study design will be investigated. Ethics and dissemination Health Research Authority approval has been obtained from the Nottingham 2 Research Ethics Committee, ref:22/EM/0157 and the trial has been registered on ISRCTN (https://doi.org/10.1186/ISRCTN16013232). Definitive findings about the feasibility of doing 24 hour pH oesophageal monitoring while doing a home sleep study will be disseminated via clinical and research networks facilitating valuable insights into the simultaneous management of both conditions. Trial registration number ISRCTN Reg No: 16013232.

Original languageEnglish
Article numbere076661
JournalBMJ Open
Volume13
Issue number8
DOIs
Publication statusPublished - 24 Aug 2023

Keywords

  • Feasibility Studies
  • GASTROENTEROLOGY
  • Health economics
  • ORAL MEDICINE
  • SLEEP MEDICINE

Fingerprint

Dive into the research topics of 'Single-centre, single-blinded, randomised, parallel group, feasibility study protocol investigating if mandibular advancement device treatment for obstructive sleep apnoea can reduce nocturnal gastro-oesophageal reflux (MAD-Reflux trial)'. Together they form a unique fingerprint.

Cite this